Lenograstim is indicated in adults, adolescents and children aged older than 2 years for the mobilisation of peripheral blood progenitor cells (PBPCs), for patients as well as healthy donors.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
150 - 150 ug per m² of body surface area (BSA)
From 150 To 150 ug per m² of body surface area (BSA) once every day
After chemotherapy, lenograstim should be administered daily, at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection starting within 1 to 5 days after completion of chemotherapy, according to the chemotherapy regimen administered for mobilisation.
Lenograstim should be maintained until the last leukapheresis.
Leukapheresis should be performed when the post nadir leukocyte count is rising or after assessment of CD34+ cells in blood with a validated method. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).
In PBPC mobilisation with lenograstim alone, lenograstim should be administered daily at the recommended dose of 1.28 MIU (10 µg) per kg per day as a subcutaneous injection for 4 to 6 days. Leukapheresis should be performed between day 5 and 7.
In patients who have not had extensive chemotherapy one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).
In healthy donors, a 10µg/kg daily dose administered subcutaneously for 5-6 days allows a CD34+ cells collection ≥3 × 106/kg body weight with a single leukapheresis in 83% of subjects and with 2 leukapheresis in 97%.
Subcutaneous
19,200,000 - 19,200,000 [iU] per m² of body surface area (BSA)
From 19,200,000 To 19,200,000 [iU] per m² of body surface area (BSA) once every day
After chemotherapy, lenograstim should be administered daily, at the recommended dose of 19.2 MIU (150 µg) per m² per day as a subcutaneous injection starting within 1 to 5 days after completion of chemotherapy, according to the chemotherapy regimen administered for mobilisation.
Lenograstim should be maintained until the last leukapheresis.
Leukapheresis should be performed when the post nadir leukocyte count is rising or after assessment of CD34+ cells in blood with a validated method. For patients who have not had extensive chemotherapy, one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).
In PBPC mobilisation with lenograstim alone, lenograstim should be administered daily at the recommended dose of 1.28 MIU (10 µg) per kg per day as a subcutaneous injection for 4 to 6 days. Leukapheresis should be performed between day 5 and 7.
In patients who have not had extensive chemotherapy one leukapheresis is often sufficient to obtain the acceptable minimum yield (≥2.0 × 106 CD34+ cells per kg).
In healthy donors, a 10µg/kg daily dose administered subcutaneously for 5-6 days allows a CD34+ cells collection ≥3 × 106/kg body weight with a single leukapheresis in 83% of subjects and with 2 leukapheresis in 97%.
Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.